Kornimate/medical-research-clean huggingface dataset:
efficacy of acupuncture for shoulder pain based on remote point selection according to the meridians

Conditions: Shoulder Pain; Acupuncture; Meridians

Summary: this double blind randomized controlled trial investigates the immediate efficacy of acupuncture for shoulder pain using remote point selection based on meridian theory. a total of 90 participants with shoulder pain (numerical rating scale ≥ 4) will be randomly assigned in a 1:1:1 ratio to one of three groups: acupuncture sc, acupuncture cs, and rehabilitation. meridian selection will be determined based on the patient's most painful shoulder movement and corresponding pain location, followed by standardized distal acupoint application. outcome measures include changes in pain intensity (nrs) and shoulder range of motion assessed at baseline, post-first acupuncture, post-second acupuncture, and 30 minutes post-treatment. blinded evaluators will conduct all assessments. the study aims to assess the effectiveness of meridian-based remote acupuncture and explore its relationship with shoulder movement patterns and soft tissue involvement.


Eligibility criteria:
inclusion criteria: * participants must be at least 18 years old. * shoulder pain persisting for at least one week. * numerical rating scale (nrs) score ≥ 4. exclusion criteria: * patients with cervical radiculopathy or other localized neurological disorders affecting the upper limb. * psychiatric disorders that may interfere with examination, treatment, or evaluation of disease progression. * pregnant patients. * inability to provide informed consent.

Keywords: shoulder pain acupuncture meridians
treatment of acne vulgaris with doryx tablets compared to doxycyline hyclate

Conditions: Acne Vulgaris

Summary: randomized, multi-center, open label, active-comparator study to compare the efficacy and tolerability of doryx delayed release tablets to doxycycline hyclate in patients with moderate to severe acne vulgaris.

efficacy of doryx delayed release tablets to doxycycline hyclate will be assessed using an investigator's global assessment (iga) score and the absolute change from baseline to 12 weeks in inflammatory lesion count in patients with moderate to severe facial acne vulgaris. additionally, the absolute change from baseline to 12 weeks in non-inflammatory lesions count of doryx delayed release tablets compared to doxycycline hyclate will be evaluated.

Eligibility criteria:
inclusion criteria: * must be 12 years of age or older. * has a diagnosis of facial acne vulgaris with no more than two nodules on the face. exclusion criteria: * is allergic to tetracycline-class antibiotics or to any ingredient in the study medication. * has a history of pseudomembranous colitis or antibiotic-associated colitis. * has a history of hepatitis or liver damage or renal impairment.
symbicort onset of action 2

Conditions: Asthma

Summary: the purpose of this study is to compare the early onset of effect of symbicort compared to advair diskus and ventolin in adults with asthma


Eligibility criteria:
inclusion criteria: * at least 18 years of age * diagnosis of asthma and baseline lung function test results as determined by the protocol * required and received inhaled corticosteroids within timeframe and doses specified in the protocol exclusion criteria: * severe asthma or asthma that is markedly effected by seasonal factors * has required and received non-inhaled corticosteroids within the previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers

Keywords: asthma adults symbicort budesonide/formoterol advair diskus ventolin
recombinant human thrombopoietin in children receiving ifosfamide, carboplatin, and etoposide chemotherapy

Conditions: Germ Cell Tumors; Hepatic Cancer; Neuroblastoma; Osteosarcoma; Rhabdomyosarcoma

Summary: life-threatening thrombocytopenia (low platelet count) and neutropenia (low white blood count) remain the major dose-limiting toxicities following chemotherapy treatment for cancer. the only remedy for thrombocytopenia at present is platelet transfusion, which is effective in preventing life-threatening hemorrhage, but may lead to other complications. preclinical studies and studies in adults have shown recombinant human thrombopoietin (rhtpo) to be effective in stimulating platelet production. the initial phase of this trial will evaluate the safety of rhtpo use immediately after chemotherapy with ifosfamide, carboplatin, and etoposide in children with solid tumors and lymphomas. the second phase of the study will evaluate the effectiveness of rhtpo in decreasing the duration of low platelet count after chemotherapy.


Eligibility criteria:
inclusion criteria: * diagnosis of recurrent, refractory, or previously untreated malignant solid tumor or recurrent/refractory lymphoma for which ifosfamide, carboplatin, and etoposide chemotherapy is the most appropriate treatment. * adequate liver and kidney function. * adequate performance status.

Keywords: thrombocytopenia platelets thrombopoietin
risk factors for the development of diabetes mellitus after distal pancreatectomy

Conditions: Diabetes Mellitus

Summary: glucose homeostasis changes after distal pancreatectomy are not well understood. this study aim to identify the incidence of and risk factors for, a change in glucose homeostasis in patients who underwent distal pancreatic resection.

the development of sophisticated surgical procedures, improved postoperative care, and the capacity for early diagnosis of disease, have prolonged life expectancy after pancreatic resection. for these patients, the endocrine function of the pancreas is a critical factor that influences quality of life. in this study, the investigators recruit patients who underwent distal pancreatectomy in peking union medical college hospital within the last 10 years. demographic characteristics, operative parameters and short-term postoperative outcomes were collected in a prospective database maintained by the pancreatic surgical centre, peking union medical college hospital. these patients are followed up regularly by outpatient visiting or telephone for long-term outcomes. the primary outcome of this study is new-onset diabetes mellitus; second outcomes include impaired fasting glucose, impaired glucose tolerance, exocrine insufficiency and disease recurrence. this study aim to determine the cumulative rates of endocrine insufficiency, and identify risk factors for dm development in a large cohort of patients undergoing distal pancreatectomy.

Eligibility criteria:
inclusion criteria: * patients undergoing distal pancreatectomy exclusion criteria: * patients undergoing pancreaticoduodenectomy, middle pancreatectomy and enucleation * patients with preoperative dm * patients with functioning insulinoma and multiple endocrine neoplasia type 1

Keywords: pancreatectomy diabetes mellitus
study evaluating the tolerance and safety of enbrel (etanercept) in adults and children

Conditions: Rheumatoid Arthritis

Summary: this postmarketing surveillance study will evaluate the safety profile of enbrel (etanercept) in an indian population. it will provide surveillance on a currently approved indication for enbrel of reducing symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * inclusion in this study will be as per the approved indications in the package insert. * patients with moderately to severely active ra. * children with jra who have had an inadequate response to one or more dmards. exclusion criteria: * known hypersensitivity to etanercept or any of its components. * known significant concurrent medical disease, including: * congestive heart failure, uncontrolled angina pectoris, recent history of myocardial infarction * cancer or history of cancer * active infection * sepsis or risk of sepsis * active tuberculosis or a past history of tuberculosis * pancytopenia * females who are pregnant, breast feeding or at risk of pregnancy and not using a medically acceptable form of contraception. * patients who are planning to undergo elective surgery during the study period.

Keywords: rheumatoid arthritis juvenile rheumatoid arthritis
study of colorectal cancer screening options

Conditions: Colon Cancer

Summary: the investigators propose to evaluate guardant health's commercially available colorectal cancer screening assay(guardant shield) in individuals who are not up to date with crc screening.

the investigators propose to evaluate guardant health's commercially available colorectal cancer screening assay(guardant shield) in individuals who are not up to date with crc screening. primary objective (or aim) assess colorectal cancer screening completion among patients who are non-adherent after receiving stool test outreach, who have an upcoming clinical appointment, and who are offered a commercially available colorectal cancer blood test versus usual care (i.e. reminder to complete stool testing during their clinical appointment). secondary objectives (or aim) assess patients' and providers' perceived confidence in the test (based on available test performance characteristics) and willingness to obtain/offer the test on an on-going basis, based on qualitative interviews; assess preliminary rates of follow-up colonoscopy completion (after an initial abnormal test result) among participants allocated to the blood test vs. usual care condition.

Eligibility criteria:
inclusion criteria: * age 45-75 * received a fit test in the last 3-9 months yet did not return their fit * upcoming appointment or willing to reschedule an appointment at kpnw within 2 - 6 weeks * able and willing to provide informed consent if in the intervention arm exclusion criteria: * on kpnw's do not contact list * having a legal authorized representative * non-english speakers

Keywords: colon cancer screening
special drug use surveillance for brentuximab vedotin intravenous infusion "relapsed or refractory cd30-positive peripheral t cell lymphoma or pediatric hodgkin lymphoma"

Conditions: Peripheral T Cell Lymphoma; Pediatric Hodgkin Lymphoma

Summary: the purpose of this survey is to examine the safety of adult patients with relapsed or refractory cd30-positive peripheral t-cell lymphoma (ptcl) (excluding anaplastic large cell lymphoma (alcl)) and pediatric patients with relapsed or refractory cd30-positive ptcl or hodgkin lymphoma (hl) in the actual use of on concomitant brentuximab vedotin in routine clinical practice.

the drug being tested in this survey is called brentuximab vedotin intravenous infusion 50 mg. this intravenous infusion is being tested to treat adult patients with relapsed or refractory cd30-positive peripheral t-cell lymphoma (ptcl) (excluding anaplastic large cell lymphoma (alcl)) and pediatric patients with relapsed or refractory cd30-positive ptcl or hodgkin lymphoma (hl). this survey is an observational (non-interventional) study and will look at the safety of adult patients with relapsed or refractory cd30-positive ptcl (excluding alcl) and pediatric patients with relapsed or refractory cd30-positive ptcl or hl in the routine clinical setting. the number of observed patients will be approximately 86 as total (80; adult participants and 6; pediatric participants). this multi-center observational survey will be conducted in japan.

Eligibility criteria:
inclusion criteria: 1. participants with relapsed or refractory lymphoma. 2. cd30-positive participants. 3. participants who receive study drug after obtaining approval of cd30-positive ptcl indication of study drug. exclusion criteria: 1. participants with a history of severe hypersensitivity to brentuximab vedotin. 2. participants taking bleomycin hydrochloride treatment.
prediction of the response to a course of transcranial magnetic stimulation (rtms) based on heart rate variability

Conditions: Major Depressive Disorder

Summary: changes in heart rate variability following a single session of rtms will be tested as a predictor of response to a course of 30 rtms sessions in patients with major depressive disorder (mdd).

the objective of this study is to investigate whether acute changes in heart rate variability following a single session of repetitive transcranial magnetic stimulation (rtms) can predict the response to a 30-session course of rtms in patients with major depressive disorder (mdd) with good sensitivity and specificity. patients who are prescribed rtms to treat an episode of mdd at one of the nine participating centres will be invited to participate in the study. the protocol includes one inclusion visit and seven evaluation visits before, during, and after the course of rtms. the rtms course will last for six weeks, comprising of 30 sessions with five sessions per week. prior to the start of the rtms course, the patient will have to fill in a number of questionnaires. before the first session, heart rate variability will be assessed by recording the rr interval at rest using a heart rate belt on the armchair stimulation. a second rr interval recording will be taken immediately after the first rtms session. patients will answer questionnaires weekly and after the final rtms session to track the progression of depressive symptoms.

Eligibility criteria:
inclusion criteria: * having a prescription for a course of rtms to treat an episod of mdd * unipolar mdd confirmed according to dsm-5 criteria * moderate to severe mdd (madrs score \> 19) * no use of psychotropic medication or use stabilised (no change in dose \< 4 weeks before study entry) * able to understand, speak, read and write french * express informed consent, after a period of reflection * affiliated with a french social security scheme or beneficiary of such a scheme exclusion criteria: * history of epilepsy or convulsive seizures * previous brain surgery * history of recent cranial trauma (\< 6 months) * presence of severe suicidal ideation * psychotic disorders * metal objects in the head, eyes or brain * implanted ferromagnetic equipment (pace maker, cochlear implant, etc.) * clinical evidence of serious or uncontrolled alcohol or substance use disorders in the three months prior to the study * active withdrawal from alcohol or other substances * one or more recent rtms sessions (\< 4 weeks) * other non-drug therapy recently initiated (\< 4 weeks) to treat mdd (psychotherapy, phototherapy, vagus nerve stimulation, etc.) * prescription of cardiotropic drugs belonging to the following classes: predominantly cardiac calcium channel blockers, vaughan williams class i anti-arrhythmics and beta-blockers. * subjects in a period of relative exclusion from another protocol * adults protected by law or patients under guardianship or curatorship * subjects deprived of their liberty by judicial or administrative decision * pregnant or breast-feeding women
blood pressure and brain blood flow regulation after midodrine administration in those with spinal cord injury

Conditions: Orthostatic Intolerance

Summary: this project aims to evaluate the physiological effects of midodrine administration during orthostatic challenge in those with high level spinal cord injury. midodrine has been shown to improve orthostatic symptoms in those with spinal cord injury but the physiological mechanisms influenced have not been identified. the investigators will examine key physiological components influencing orthostatic tolerance. the investigators will do this, by measuring the baroreflex, and brain blood flow autoregulation (the ability to maintain brain blood flow) before during and after the sit-up test. two sit-up tests will occur; one before midodrine administration, and one after administration of a 10mg dose of midodrine.


Eligibility criteria:
inclusion criteria: * to be included in the study, participants must have sustained a traumatic spinal cord injury within the ages of 18-49 years. * also, participants must have an injury level above the 6th thoracic vertebrae and be a non-smoker for a minimum of one year. exclusion criteria: * any participants with a history of cardiovascular disease, pulmonary disease or diabetes mellitus will not be eligible. * also, participants will not be eligible to take part in study if they experiences acute distress, or are taking medications known to influence cardiovascular function. * patient will be not eligible for the study if he/she has known adverse reaction to midodrine.

Keywords: orthostatic intolerance in people with spinal cord injury
prevention of atrial fibrillation in patients undergoing thoracic surgery for lung cancer

Conditions: Lung Cancer; Atrial Fibrillation

Summary: the aim of this study is to assess whether prophylactic treatment with metoprolol or losartan is able to reduce the incidence of atrial fibrillation (af) in patients undergoing thoracic surgery for lung cancer, showing elevated plasma levels in nt probrain natriuretic peptide (nt-probnp), measured in the perioperative period.

postoperative atrial fibrillation is one of the most common complication after thoracic surgery for lung cancer, with an incidence ranging from 8 to 20% after lobectomy and up to 42% after pneumonectomy. in a recent study we demonstrated that a high perioperative plasma levels of nt-probnp is able to identify patients at risk for af (incidence of 65%). it has also been demonstrated that the renin-angiotensin system may play an important role in the pathophysiology of atrial fibrillation and that angiotensin converting enzyme inhibitors (acei) and angiotensin ii receptor blockers (arbs) are able to prevent atrial fibrillation in patients with heart failure, after myocardial infarction, in hypertensive patients and after electrical cardioversion.

Eligibility criteria:
inclusion criteria: * patients of both sexes with age ≥ 18 years * thoracic surgery for lung cancer * evidence of elevated perioperative nt-probnp * written informed consent exclusion criteria: * hypersensitivity and / or intolerance to metoprolol or losartan * history of heart failure * left ventricular ejection fraction \<50% measured by echocardiographic techniques (simpson rule) * permanent atrial fibrillation * antiarrhythmic therapy * current therapy with beta-blockers, angiotensin ii receptor blockers and angiotensin-converting enzyme inhibitors * systolic blood pressure \<95 mmhg * pregnant and lactating women additional exclusion criteria for therapy with beta-blocker: * history of sick sinus syndrome, evidence of av-block grade ii or greater * heart rate \<65 b / m * history of bronchial asthma, severe bronchopneumopathy, evidence of bronchospasm

Keywords: fap= post-surgery atrial fibrillation acei= angiotensin converting enzyme-inhibitors arbs= angiotensin ii receptor blockers nt-probnp= brain natriuretic peptide
phase 3 trial of cannabidiol (cbd; gwp42003-p) for infantile spasms: open-label extension phase (gwpcare7)

Conditions: Infantile Spasms

Summary: this trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase, and an open-label extension phase. the open-label extension phase only will be described in this record. all participants will receive gwp42003-p.


Eligibility criteria:
only participants who completed the pilot or pivotal phases of the trial may proceed to take part in this open-label extension phase of the trial. key eligibility criteria for the blinded phase were as follows: key inclusion criteria: * participant is diagnosed with is and has failed to respond adequately following treatment with 1 or more approved is therapies. key exclusion criteria: * participant is currently taking or has taken clobazam or any mammalian target of rapamycin (mtor) inhibitor within the 2 weeks prior to the screening visit. * participant has a qt interval, corrected for heart rate with bazett's formula (qtcb), of 460 msec or greater on ecg. * participant's caregiver is currently giving or has given recreational or medicinal cannabis, or synthetic cannabinoid-based medications, within the 1 month prior to the screening visit. * participant's caregiver is unwilling to abstain from giving the participant (including the participant's mother abstaining themselves, if breastfeeding)recreational or medicinal cannabis, or synthetic cannabinoid-based medications (other than the study drug) during the trial. * participant has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the study drug, such as sesame oil. * participant has significantly impaired hepatic function at the screening visit. * participant has received an investigational medicinal product as part of a clinical trial within a minimum of 5 half-lives prior to the screening visit.

Keywords: gwp42003-p cannabidiol
outcomes of obstetric patients with covid-19 disease in the icu

Conditions: COVID-19; Obstetric Anesthesia Problems; Intensive Care Unit; Morality

Summary: although several studies are conducted in the general population researching the clinical and laboratory parameters predicting the progression to severe disease in covid-19, the data are very few in obstetric patients. therefore,the investigators aimed to evaluate the characteristics, prognosis, laboratory parameters, and mortality of obstetric patients followed up in the intensive care unit (icu) due to severe covid-19 disease and to determine the factors affecting mortality.

this study was a single-center, retrospective, and observational trial and carried out with the principles of the declaration of helsinki. all patient demographics and information were analyzed retrospectively from the patient files. demographic data, obstetric histories, comorbidities, treatments received in the intensive care unit (icu), delivery types, anesthesia types, and outcomes of newborns and mothers were retrospectively evaluated from the medical records. the need for the mechanical ventilator, the length of stay in the icu, and outcomes of mothers were recorded. laboratory findings were noted on the first day of admission to the icu, including routine complete blood count, liver and kidney function, coagulation parameters, c-reactive protein (crp), and albumin levels. then neutrophil to lymphocyte (n/l) ratio, platelet to lymphocyte (p/l) ratio, and crp to albumin (crp/alb) ratio were calculated. deceased patients were evaluated in detail.

Eligibility criteria:
inclusion criteria: * obstetric patients (during the pregnancy and postpartum period, from the beginning of pregnancy and up to 42 days after delivery) hospitalized in the intensive care unit of our tertiary care hospital * patients who had positive pcr nasopharyngeal swabs for covid-19 exclusion criteria: * patients who had negative pcr nasopharyngeal swabs for covid-19 and were clinically suspicious
dental isolation methods in pediatric patients

Conditions: Dental Plaque; Calculus, Dental; Aerosol Disease

Summary: the purpose of this study is to collect, measure, and assess the environmental spatter produced during dental appointments under different isolation methods used in pediatric dentistry, to compare the effectiveness of aerosol reduction between these methods, to identify the most effective way to manage aerosol during dental prophylaxis for pediatric patients and to provide clinical evidence to facilitate practice guidelines in dentistry related to covid-19.


Eligibility criteria:
inclusion criteria: * asa 1 patients * receiving dental prophylaxis or restorative procedure not requiring sedation or nitrous oxide * ability to cooperate in the dental chair * parents speak/read either english or spanish and consent to study * child, when age appropriate, can assent to study exclusion criteria: * patients that do not meet the above criteria (including inability to cooperate or special health care need) * parents that do not speak/read either english or spanish * children that do not assent (when age appropriate) to the study

Keywords: infection control dental hygiene spatter aerosol